Multiple metastases in a novel LNCaP model of human prostate cancer

Zou,Minhong; Jiao,Ju; Zou,Qiong; Xu,Yan; Cheng,Muhua; Xu,Jiehua; Zhang,Yong

doi:10.3892/or.2013.2305

Multiple metastases in a novel LNCaP model of human prostate cancer

Authors:
- Minhong Zou
- Ju Jiao
- Qiong Zou
- Yan Xu
- Muhua Cheng
- Jiehua Xu
- Yong Zhang
View Affiliations

Affiliations: Department of Nuclear Medicine, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510630, P.R. China
Published online on: February 26, 2013 https://doi.org/10.3892/or.2013.2305
Pages: 615-622

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Metastasis is a frequent and lethal consequence of prostate cancer. Current treatments for metastasis are palliative only. Thus, experimental animal models of metastatic prostate cancer are required for investigations of its pathogenesis and for the development of treatment strategies; however, few models exist at present. In the present study, the LNCaP prostate cancer cell line was co-transfected with a PGK-luciferase-GFP lentivirual vector (LNCaP-luc). Repeated subcutaneous injections of LNCaP-luc cells with Matrigel in nude mice followed by isolation of the cells from tumors resulted in the generation of the LNCaP1-luc cell line. We used CCK-8 and Transwell migration assays, western blot analysis and polymerase chain reaction to detect differences in the characteristics between the LNCaP-luc and LNCaP1-luc cells, and used LNCaP cells to generate a mouse model of metastatic prostate cancer by intracardiac injection. Metastasis was evaluated by bioluminescence imaging, and histological and immunohistochemical staining. the characteristics of the LNCaP1-luc cells differed from those of LNCaP cells, and LNCaP1-luc cells showed increased cell proliferation, cell invasion, tumorigenicity and metastasis potential, and underwent epithelial-mesenchymal transition. In addition, the LNCaP1-luc cells induced multiple metastases in mice when injected into the left cardiac muscle.

View Figures

View References

1	Marech I, Vacca A, Ranieri G, Gnoni A and Dammacco F: Novel strategies in the treatment of castration-resistant prostate cancer (Review). Int J Oncol. 40:1313–1320. 2012.PubMed/NCBI
2	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
3	Wang Q, Li W, Zhang Y, et al: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 138:245–256. 2009. View Article : Google Scholar : PubMed/NCBI
4	Power CA, Pwint H, Chan J, et al: A novel model of bone-metastatic prostate cancer in immunocompetent mice. Prostate. 69:1613–1623. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zuluaga MF, Gabriel D and Lange N: Enhanced prostate cancer targeting by modified protease sensitive photosensitizer prodrugs. Mol Pharm. 9:1570–1579. 2012. View Article : Google Scholar : PubMed/NCBI
6	Pienta KJ, Abate-Shen C, Agus DB, et al: The current state of preclinical prostate cancer animal models. Prostate. 68:629–639. 2008. View Article : Google Scholar : PubMed/NCBI
7	Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S and Contag CH: Animal models of bone metastasis. Cancer. 97:748–757. 2003. View Article : Google Scholar : PubMed/NCBI
8	Blouin S, Basle MF and Chappard D: Rat models of bone metastases. Clin Exp Metastasis. 22:605–614. 2005. View Article : Google Scholar : PubMed/NCBI
9	Singh AS, Macpherson GR, Price DK, Schimel D and Figg WD: Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis. Oncol Rep. 15:519–524. 2006.PubMed/NCBI
10	Song H, Shahverdi K, Huso DL, et al: An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer. Clin Cancer Res. 14:6116–6124. 2008. View Article : Google Scholar : PubMed/NCBI
11	Arguello F, Baggs RB and Frantz CN: A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 48:6876–6881. 1988.PubMed/NCBI
12	Jenkins DE, Hornig YS, Oei Y, Dusich J and Purchio T: Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune- deficient mice. Breast Cancer Res. 7:R444–R454. 2005. View Article : Google Scholar : PubMed/NCBI
13	Fritz V, Louis-Plence P, Apparailly F, et al: Micro-CT combined with bioluminescence imaging: a dynamic approach to detect early tumor-bone interaction in a tumor osteolysis murine model. Bone. 40:1032–1040. 2007. View Article : Google Scholar : PubMed/NCBI
14	Wetterwald A, van der Pluijm G, Que I, et al: Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol. 160:1143–1153. 2002. View Article : Google Scholar : PubMed/NCBI
15	Xing N, Chen Y, Mitchell SH and Young CY: Quercetin inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Carcinogenesis. 22:409–414. 2001. View Article : Google Scholar : PubMed/NCBI
16	Emadi BM, Soheili ZS, Schmitz I, Sameie S and Schulz WA: Snail regulates cell survival and inhibits cellular senescence in human metastatic prostate cancer cell lines. Cell Biol Toxicol. 26:553–567. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chen JN, Jiang Y, Li HG, et al: Epstein-Barr virus genome polymorphisms of Epstein-Barr virus-associated gastric carcinoma in gastric remnant carcinoma in Guangzhou, Southern China, an endemic area of nasopharyngeal carcinoma. Virus Res. 160:191–199. 2011. View Article : Google Scholar
18	Yang M, Jiang P, Sun FX, et al: A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res. 59:781–786. 1999.PubMed/NCBI
19	Guo Z, Yang X, Sun F, et al: A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69:2305–2313. 2009. View Article : Google Scholar : PubMed/NCBI
20	Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S and Chung LW: Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer. 57:406–412. 1994. View Article : Google Scholar : PubMed/NCBI
21	Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H and Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55:3068–3072. 1995.PubMed/NCBI
22	Brown RS, Edwards J, Dogan A, et al: Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol. 198:237–244. 2002. View Article : Google Scholar : PubMed/NCBI
23	Ullen A, Farnebo M, Thyrell L, et al: Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro. Int J Oncol. 37:15–20. 2010. View Article : Google Scholar
24	Liu Y, Wu X, Dong Z and Lu S: The molecular mechanism of Vav3 oncogene on upregulation of androgen receptor activity in prostate cancer cells. Int J Oncol. 36:623–633. 2010.PubMed/NCBI
25	Martin TA and Jiang WG: Anti-cancer agents in medicinal chemistry (Formerly current medicinal chemistry - Anti-cancer agents). Anticancer Agents Med Chem. 10:12010.PubMed/NCBI
26	Sturge J, Caley MP and Waxman J: Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol. 8:357–368. 2011. View Article : Google Scholar : PubMed/NCBI
27	Wu TT, Sikes RA, Cui Q, et al: Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer. 77:887–894. 1998. View Article : Google Scholar
28	Kleinman HK and Martin GR: Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 15:378–386. 2005. View Article : Google Scholar : PubMed/NCBI
29	Tilghman RW, Blais EM, Cowan CR, et al: Matrix rigidity regulates cancer cell growth by modulating cellular metabolism and protein synthesis. PLoS One. 7:e372312012. View Article : Google Scholar : PubMed/NCBI
30	Thalmann GN, Anezinis PE, Chang SM, et al: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54:2577–2581. 1994.PubMed/NCBI
31	Xu J, Wang R, Xie ZH, et al: Prostate cancer metastasis: role of the host microenvironment in promoting epithelial to mesenchymal transition and increased bone and adrenal gland metastasis. Prostate. 66:1664–1673. 2006. View Article : Google Scholar : PubMed/NCBI
32	Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
33	Kogan-Sakin I, Tabach Y, Buganim Y, et al: Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 18:271–281. 2011. View Article : Google Scholar : PubMed/NCBI
34	Kong D, Banerjee S, Ahmad A, et al: Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One. 5:e124452010. View Article : Google Scholar : PubMed/NCBI
35	Birchmeier C, Birchmeier W and Brand-Saberi B: Epithelial-mesenchymal transitions in cancer progression. Acta Anat. 156:217–226. 1996. View Article : Google Scholar : PubMed/NCBI
36	Grille SJ, Bellacosa A, Upson J, et al: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 63:2172–2178. 2003.PubMed/NCBI
37	Guarino M, Rubino B and Ballabio G: The role of epithelial-mesenchymal transition in cancer pathology. Pathology. 39:305–318. 2007. View Article : Google Scholar : PubMed/NCBI
38	Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 24:7443–7454. 2005.
39	Wells A, Yates C and Shepard CR: E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas. Clin Exp Metastasis. 25:621–628. 2008. View Article : Google Scholar : PubMed/NCBI